Have a feature idea you'd love to see implemented?
Let us know!
CARA Cara Therapeutics Inc
Price (delayed)
$4.78
Market cap
$21.85M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$21.12
Enterprise value
$27.29M
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is
Highlights
The gross margin has increased by 35% year-on-year and by 15% since the previous quarter
The quick ratio has increased by 22% year-on-year and by 8% since the previous quarter
Cara Therapeutics's equity has plunged by 99% YoY and by 94% from the previous quarter
The revenue has dropped by 59% year-on-year and by 21% since the previous quarter
Key stats
What are the main financial stats of CARA
Market
Valuations
Earnings
Shares outstanding
4.57M
Market cap
$21.85M
Enterprise value
$27.29M
Price to earnings (P/E)
N/A
Price to book (P/B)
30.9
Price to sales (P/S)
2.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.14
Revenue
$8.69M
Gross profit
$7.46M
Net income
-$95.53M
EBIT
-$89.07M
EBITDA
-$87.18M
Free cash flow
-$77.34M
Per share
Balance sheet
Liquidity
EPS
-$21.12
EPS diluted
-$21.12
Free cash flow per share
-$16.92
Book value per share
$0.15
Revenue per share
$1.9
TBVPS
$11.23
Total assets
$51.33M
Total liabilities
$50.62M
Debt
$44M
Equity
$707,000
Working capital
$37.87M
Debt to equity
62.23
Current ratio
4.77
Quick ratio
4.47
Net debt/EBITDA
-0.06
Margins
Efficiency
Dividend
EBITDA margin
-1,003.6%
Gross margin
85.9%
Net margin
-1,099.8%
Operating margin
-1,063.2%
Return on assets
-112.5%
Return on equity
-385.2%
Return on invested capital
-133%
Return on capital employed
-215.7%
Return on sales
-1,025.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CARA stock price
How has the Cara Therapeutics stock price performed over time
Intraday
3.91%
1 week
7.17%
1 month
-5.72%
1 year
-28.66%
YTD
-21.9%
QTD
-21.9%
Financial performance
How have Cara Therapeutics's revenue and profit performed over time
Revenue
$8.69M
Gross profit
$7.46M
Operating income
-$92.35M
Net income
-$95.53M
Gross margin
85.9%
Net margin
-1,099.8%
CARA's net margin has dropped by 100% year-on-year and by 9% since the previous quarter
Cara Therapeutics's operating margin has plunged by 88% YoY and by 6% from the previous quarter
The revenue has dropped by 59% year-on-year and by 21% since the previous quarter
CARA's gross profit is down by 45% YoY and by 9% from the previous quarter
Growth
What is Cara Therapeutics's growth rate over time
Valuation
What is Cara Therapeutics stock price valuation
P/E
N/A
P/B
30.9
P/S
2.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.14
Cara Therapeutics's EPS has increased by 18% YoY and by 14% from the previous quarter
Cara Therapeutics's equity has plunged by 99% YoY and by 94% from the previous quarter
CARA's P/S is 79% below its 5-year quarterly average of 11.5 but 21% above its last 4 quarters average of 2.0
The revenue has dropped by 59% year-on-year and by 21% since the previous quarter
Efficiency
How efficient is Cara Therapeutics business performance
Cara Therapeutics's ROS has plunged by 87% YoY and by 6% from the previous quarter
Cara Therapeutics's return on equity has shrunk by 60% QoQ
CARA's ROA is down by 41% YoY and by 2.3% QoQ
CARA's return on invested capital is up by 22% year-on-year and by 20% since the previous quarter
Dividends
What is CARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CARA.
Financial health
How did Cara Therapeutics financials performed over time
Cara Therapeutics's total liabilities has soared by 70% YoY but it has decreased by 17% from the previous quarter
The total assets has plunged by 55% YoY and by 29% from the previous quarter
Cara Therapeutics's equity has plunged by 99% YoY and by 94% from the previous quarter
CARA's debt is down by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.